Answers are grounded in this paper and cite their sources.
Demonstrates dose-dependent activity of recombinant ADAMTS-13 in congenital thrombotic thrombocytopenic purpura, suggesting effective von Willebrand factor processing.
[U/mL]) and area under the concentration-time curve (AUC [h∙U/mL]). Dose-related increases of individual ADAMTS-13:Ag and activity were observed and reached a maximum within 1 hour. With escalating BAX 930 doses administered, a dose-dependent persistence of ADAMTS-13-mediated von Willebrand factor (VWF) cleavage products and reduced VWF multimeric size were observed. This study demonstrated that pharmacokinetic parameters of BAX 930 were comparable to those estimated in previous plasma infusion studies and provided evidence of pharmacodynamic activity. This study was registered at www.clinicaltrials.gov as #NCT02216084.
No takes yet. Share an insight, caveat, or question.
Scully et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: